JQ1 and G781 are toxic in vivo. A, Changes in serum M-spike levels (a marker of tumor burden) relative to day 0 in 71–82 week-old de novo Vk*MYC mice treated twice daily for 2 weeks with increasing doses of the EP300 inhibitor G781 (shaded area). B, Day 14 blood cell and platelet counts for the same mice treated in A. C, Day 14 serum M-spike values relative to day 0 for WT mice transplanted with Vk29790 tumor line and treated twice daily for 2 weeks with vehicle, BET inhibitor (iBET-762), EP300 inhibitor (G781), or the combination. D, Survival curves for the same WT mice transplanted and treated in C. E, Day 14 decreases in % body weight relative to day 0 for same mice treated in C and D. For all panels, each dot represents an individual mouse. Survival curve statistics in D were derived from the Mantel–Cox log-ranked χ2 test. All other P values were determined by an unpaired t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant. Error bars display SD.